Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Mar;93(3):465–472. doi: 10.1111/j.1476-5381.1988.tb10300.x

Sulphasalazine and PhCL28A inhibit the formation of ethanol- and phenylbutazone-induced rat gastric ulcers: lack of involvement of endogenous prostaglandins?

C N Berry 1, M Prouteau 1, K G Lloyd 1
PMCID: PMC1853854  PMID: 2897215

Abstract

1. The effects of sulphasalazine (SZP) and PhCL28A on macroscopic lesion formation and ex vivo prostaglandin inactivation were studied in the ethanol (ETOH) and phenylbutazone (PBT) models of gastric ulcers in the rat. Prostaglandin 'synthesis' during homogenisation of the stomachs was also studied in the latter model. 2. Both PhCL28A and SZP when injected i.p. prevented the formation of ETOH- and PBT-induced gastric ulcers with ED50 values of 13 and 41 mgkg-1 (vs ETOH) and 3 and 32 mgkg-1 (vs PBT) for PhCL28A and SZP respectively. However, neither compound was active orally in the dose ranges used (up to 30 mg kg-1 for PhCL28A and 100 mg kg-1 for SZP). 3. Irrespective of the route of administration, SZP (100 mg kg-1) and PhCL28A (30 mg kg-1) produced slight but statistically significant decreases in ex vivo prostaglandin inactivation by 100,000 g cytosolic supernatants prepared from stomachs not receiving ulcerogen. When tested in vitro, PhCL28A (IC50 = 230 nM) was approximatively 480 times mor potent than SZP (IC50 = 110 microM) against rat stomach cytosolic prostaglandin inactivation. 4. Both ETOH (50%, 5 ml kg-1, orally) and PBT (200 mg kg-1, orally) significantly decreased ex vivo gastric cytosolic prostaglandin inactivation. PhCL28A (30 mg kg-1, orally or i.p.) decreased prostaglandin inactivation still further after ulcerogen treatment except when given i.p. before ETOH treatment. SZP (100 mg kg-1) had a similar effect when given orally before PBT treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
465

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett A., Stamford I. F., Stockley H. L. Estimation and characterization of prostaglandins in the human gastrointestinal tract. Br J Pharmacol. 1977 Dec;61(4):579–586. doi: 10.1111/j.1476-5381.1977.tb07551.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry C. N., Hoult J. R., Phillips J. A., McCarthy T. M., Agback H. Highly potent inhibition of prostaglandin 15-hydroxydehydrogenase in-vitro and of prostaglandin inactivation in perfused lung by the new azobenzene analogue, Ph CL 28A. J Pharm Pharmacol. 1985 Sep;37(9):622–628. doi: 10.1111/j.2042-7158.1985.tb05098.x. [DOI] [PubMed] [Google Scholar]
  3. Carmichael H. A., Nelson L. M., Russel R. I. Cimetidine and prostaglandin: evidence for different modes of action on the rat gastric mucosa. Gastroenterology. 1978 Jun;74(6):1229–1232. [PubMed] [Google Scholar]
  4. Del Soldato P., Foschi D., Varin L., Daniotti S. Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone. Agents Actions. 1985 Jul;16(5):393–396. doi: 10.1007/BF01982878. [DOI] [PubMed] [Google Scholar]
  5. Dighe K. K., Emslie H. A., Henderson L. K., Simon L. The development of antisera to prostaglandins B2 and F2alpha and their analysis using solid-phase and double antibody radioimmunoassay methods. Br J Pharmacol. 1975 Dec;55(4):503–514. doi: 10.1111/j.1476-5381.1975.tb07425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldman P., Peppercorn M. A. Drug therapy: Sulfasalazine. N Engl J Med. 1975 Jul 3;293(1):20–23. doi: 10.1056/NEJM197507032930105. [DOI] [PubMed] [Google Scholar]
  7. Hawkey C. J., Rampton D. S. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology. 1985 Nov;89(5):1162–1188. doi: 10.1016/0016-5085(85)90225-2. [DOI] [PubMed] [Google Scholar]
  8. Hoult J. R., Moore P. K. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol. 1980 Apr;68(4):719–730. doi: 10.1111/j.1476-5381.1980.tb10865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoult J. R., Moore P. K., Marcus A. J., Watt J. On the effect of sulphasalazine on the prostaglandin system and the defective prostaglandin inactivation observed in experimental ulcerative colitis. Agents Actions Suppl. 1979;(4):232–244. [PubMed] [Google Scholar]
  10. Hoult J. R., Moore P. K. Pathways of prostaglandin F2alpha metabolism in mammalian kidneys. Br J Pharmacol. 1977 Dec;61(4):615–626. doi: 10.1111/j.1476-5381.1977.tb07555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hoult J. R., Moore P. K. Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol. 1978 Sep;64(1):6–8. doi: 10.1111/j.1476-5381.1978.tb08633.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Konturek S. J., Radecki T., Brzozowski T., Drozdowicz D., Piastucki I., Muramatsu M., Tanaka M., Aihara H. Antiulcer and gastroprotective effects of solon, a synthetic flavonoid derivative of sophoradin. Role of endogenous prostaglandins. Eur J Pharmacol. 1986 Jun 17;125(2):185–192. doi: 10.1016/0014-2999(86)90026-9. [DOI] [PubMed] [Google Scholar]
  13. Matsuo Y., Kuwayama H., Itoh H., Seki A., Fukuda S., Kawasaki T., Hotta T., Ohsaka Y., Komatsu K. Gastric anti-ulcer and cytoprotective properties of 2-(3,4-dimethoxyphenyl)-5-methyl-thiazolidine-4-one in rat experimental ulcers. Arzneimittelforschung. 1986 Aug;36(8):1236–1240. [PubMed] [Google Scholar]
  14. Miller T. A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983 Nov;245(5 Pt 1):G601–G623. doi: 10.1152/ajpgi.1983.245.5.G601. [DOI] [PubMed] [Google Scholar]
  15. Ogle C. W., Cho C. H. Effects of sulphasalazine on stress ulceration and mast cell degranulation in rat stomach. Eur J Pharmacol. 1985 Jun 7;112(2):285–286. doi: 10.1016/0014-2999(85)90512-6. [DOI] [PubMed] [Google Scholar]
  16. Olson G. A., Leffler C. W., Fletcher A. M. Gastroduodenal ulceration in rabbits producing antibodies to prostaglandins. Prostaglandins. 1985 Mar;29(3):475–480. doi: 10.1016/0090-6980(85)90105-4. [DOI] [PubMed] [Google Scholar]
  17. Robert A. Cytoprotection by prostaglandins. Gastroenterology. 1979 Oct;77(4 Pt 1):761–767. [PubMed] [Google Scholar]
  18. Sircar J. C., Schwender C. F., Carethers M. E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170–172. doi: 10.1016/0006-2952(83)90673-1. [DOI] [PubMed] [Google Scholar]
  19. Stenson W. F., Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982 Feb;69(2):494–497. doi: 10.1172/JCI110474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stenson W. F., Mehta J., Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol. 1984 Feb 1;33(3):407–412. doi: 10.1016/0006-2952(84)90233-8. [DOI] [PubMed] [Google Scholar]
  21. Strub K. M., Müller R. K. Relation between ulcerogenic activity of various NSAID and their potency as inhibitors of prostaglandin synthesis in vivo. Agents Actions Suppl. 1979;(4):245–254. [PubMed] [Google Scholar]
  22. Wallace J. L., Whittle B. J. Role of prostanoids in the protective actions of BW755C on the gastric mucosa. Eur J Pharmacol. 1985 Sep 10;115(1):45–52. doi: 10.1016/0014-2999(85)90582-5. [DOI] [PubMed] [Google Scholar]
  23. Whittle B. J., Boughton-Smith N. K., Moncada S., Vane J. R. Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro. Prostaglandins. 1978 Jun;15(6):955–967. doi: 10.1016/0090-6980(78)90038-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES